Issue Date: October 3, 2016
Canon invests in T2 Biosystems
Canon USA has purchased a nearly 20% stake in T2 Biosystems, a maker of time-domain nuclear magnetic resonance diagnostics, for $40 million. T2 has worked with the molecular diagnostics arm of Canon since 2015 to develop a test panel for Lyme disease. T2 expects to use the funds to grow its business and launch a sepsis detection panel in 2017. The firm’s technology was developed by scientists at Massachusetts General Hospital and MIT.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society